Table 2.
Chemokine receptor expression levelsa
| Chemokine Receptor | Controls | ESRD | ESRD No Infection | ESRD Recurrent Infection | ESRD Hemodialysis | ESRD Peritoneal Dialysis |
|---|---|---|---|---|---|---|
| CCR1 | 23.9 ± 3.6 (15) | 21.1 ± 2.3 (29) | 22.2 ± 2.7 (20) | 18.5 ± 4.4 (9) | 22.1 ± 2.8 (20) | 18.7 ± 4.0 (9) |
| CCR2 | 74.7 ± 6.1 (16) | 61.6 ± 6.1 (30)b | 68.8 ± 7.7 (21) | 44.5 ± 7.7 (9)b | 63.1 ± 8.1 (21) | 58.0 ± 8.4 (9) |
| CCR5 | 4.0 ± 1.1 (16) | 3.5 ± 0.7 (29) | 2.2 ± 0.5 (20) | 6.5 ± 1.5 (9) | 3.8 ± 0.8 (20) | 2.9 ± 1.31 (9) |
| CXCR1 | 276.4 ± 21.4 (16) | 214.8 ± 18.3 (30)b | 233.1 ± 18.9 (21) | 172.1 ± 38.8 (9)b | 209.0 ± 21.8 (21) | 228.4 ± 35.3 (9) |
| CXCR2 | 69.1 ± 17.76 (8) | 61.3 ± 6.7 (20) | 59.0 ± 4.0 (15) | 68.2 ± 21.1 (5) | 63.5 ± 9.8 (12) | 58.0 ± 8.8 (8) |
a
Mean ± SEM from indicated number of control subjects or patients (number of control subjects or patients in parentheses). Chemokine receptor expression values are reported as mean fluorescence intensity. Significances for control versus ESRD were determined using the Mann–Whitney nonparametric test. Significances for all subgroup analyses were determined using the Kruskal–Wallis nonparametric test followed by pairwise multiple comparisons using the Mann–Whitney test.
b
P < 0.017 versus control.